Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 2025 earnings call. I will now turn the program over to Brian Girardo, Chief Financial Officer and Chief Operating Officer. Thank you, Operator, and thank you all for joining us this afternoon. I am joined on today's call by Faheem Hasne, Gossamer's Founder, Chairman, and Chief Executive Officer, Dr. Richard Aranda, Chief Medical Officer, Karen Peterson, Executive Vice President, Regulatory Affairs, and Bob Smith, Chief Commercial Officer. Earlier this afternoon, Gossamer Bio issued a press release announcing its first quarter 2025 financial results and provided a corporate update. Please note that certain information discussed on the call today is covered under the same provision of the Private Securities Litigation Reform Act. We caution listeners that during the call, Gossamer Management will be making forward-looking statements. Actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by statements contained in Gossamer's news releases, SEC filings, including the annual report on Form 10-K and subsequent filings. This conference call also contains time-sensitive information that may be accurate only for a limited period of time. Gossamer Bio undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now, I'd like to turn it over to Fahim. Thank you, Brian. Good afternoon, everyone, and welcome to our first quarter 2025 earnings call. We're very excited to provide an update on the significant progress and momentum with serolutinib, which is a...